Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Continuous prediction of secondary progression in the individual course of multiple sclerosis.

Skoog B, Tedeholm H, Runmarker B, Odén A, Andersen O.

Mult Scler Relat Disord. 2014 Sep;3(5):584-92. doi: 10.1016/j.msard.2014.04.004. Epub 2014 May 9.

PMID:
26265270
2.

The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O.

J Neurol. 2015 May;262(5):1148-63. doi: 10.1007/s00415-015-7674-y. Epub 2015 Feb 26.

PMID:
25712541
3.

Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy.

Novakova L, Skoog B, Runmarker B, Ekholm S, Winblad S, Lisovskaja V, Andersen O.

Mult Scler. 2014 Apr;20(4):496-500. doi: 10.1177/1352458513496345. Epub 2013 Jul 18.

PMID:
23868138
4.

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O.

Mult Scler. 2013 May;19(6):765-74. doi: 10.1177/1352458512463764. Epub 2012 Nov 1.

5.

A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.

Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O.

Brain. 2012 Mar;135(Pt 3):900-11. doi: 10.1093/brain/awr336.

PMID:
22366800
6.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators..

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
7.

[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].

Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Oluf A.

Lakartidningen. 2007 May 30-Jun 3;104(22):1684-8. Swedish. No abstract available.

PMID:
17601317
8.

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

Eriksson M, Andersen O, Runmarker B.

Mult Scler. 2003 Jun;9(3):260-74. Erratum in: Mult Scler. 2003 Dec;9(6):641.

PMID:
12814173
9.

Temporal speech characteristics of individuals with multiple sclerosis and ataxic dysarthria: 'scanning speech' revisited.

Hartelius L, Runmarker B, Andersen O, Nord L.

Folia Phoniatr Logop. 2000 Sep-Oct;52(5):228-38.

PMID:
10965176
10.

Prevalence and characteristics of dysarthria in a multiple-sclerosis incidence cohort: relation to neurological data.

Hartelius L, Runmarker B, Andersen O.

Folia Phoniatr Logop. 2000 Jul-Aug;52(4):160-77.

PMID:
10782009
11.

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S.

Neurology. 1996 Oct;47(4):895-900.

PMID:
8857715
12.

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S.

Mult Scler. 1996 Jul;1(6):348. No abstract available.

PMID:
9345415
13.
14.

Prediction of outcome in multiple sclerosis based on multivariate models.

Runmarker B, Andersson C, Odén A, Andersen O.

J Neurol. 1994 Oct;241(10):597-604.

PMID:
7836963
15.

HLA and prognosis in multiple sclerosis.

Runmarker B, Martinsson T, Wahlström J, Andersen O.

J Neurol. 1994 May;241(6):385-90.

PMID:
7931434
16.
17.

Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis.

Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B.

Neuroepidemiology. 1991;10(2):62-5.

PMID:
2062419
18.

Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden.

Svenningsson A, Runmarker B, Lycke J, Andersen O.

Acta Neurol Scand. 1990 Sep;82(3):161-8.

PMID:
2270743

Supplemental Content

Loading ...
Support Center